Troubles continue for voice recognition technology provider Lernout & Hauspie (HNN 10/18/00). With the U.S. Securities and Exchange Commission and the Easdaq stock exchange both investigating accusations of questionable accounting practices
Troubles continue for voice recognition technology provider Lernout & Hauspie (HNN 10/18/00). With the U.S. Securities and Exchange Commission and the Easdaq stock exchange both investigating accusations of questionable accounting practices by L&H, Easdaq and Nasdaq have halted trading of the company's shares. Trading will not resume on either exchange until the firm has fully satisfied Nasdaq's request for additional information.
L&H, which is also facing a number of class action lawsuits, is in the process of restating its financial results from the past two and a half years. The beleaguered VR vendor is considering measures including staffing cuts and pulling back product lines to speed its return to profitability.
© 2000 Miller Freeman Inc.
11/29/00, Issue # 117, page 5.
Collaboration Between Philips and Polarean Allows Routine MRI Access to High-Res Imaging of Lung VentilationJune 2nd 2023
The combination of Philips’ MR 7700 multi-nuclei scanner with the FDA-approved Xenoview hyperpolarized Xenon magnetic resonance imaging (MRI) contrast agent may facilitate earlier diagnosis and intervention for patients with obstructive lung diseases.
The Reading Room Podcast: Emerging Trends in the Radiology WorkforceFebruary 11th 2022
Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer ImagingMay 30th 2023
Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.
2 Clarke Drive
Cranbury, NJ 08512